Phase Ib Trial of SL-172154 With Mirvetuximab Soravtansine or Pegylated Liposomal Doxorubicin in

Clinical Editorial

British Journal of Cancer, Published online: 08 April 2026; doi:10.1038/s41416-026-03430-0 Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Front ImmunolRelated by Drugdoxorubicin

IL-8–positive CAFs drive chemotherapy‑induced tumor progression in breast cancer: multi‑omics inte

Oncology • 20 Jul 2026

bioRxivRelated by Drugdoxorubicin

AAV VP1 unique region (VP1u) determines GPR108 dependence for AAV transduction of human airway epithelium and its rescue by Doxorubicin

Research Highlights • 10 Jul 2026

bioRxivRelated by Drugdoxorubicin

Ultrasound-Triggered Chemotherapy Extends Survival in a Genetically Engineered Glioblastoma Model

Research Highlights • 09 Jul 2026

DailyMedRelated by Drugdoxorubicin

Doxorubicin Hydrochloride Injectable, Liposomal (Zydus) Updated

Pharmacology • 27 Mar 2026

JAHARelated by Drugdoxorubicin

Sympathetic Overdrive, Vascular Dysfunction, and Exercise Intolerance in Long-Term Breast Cancer

Cardiology • 13 Mar 2026